Equities Analysts Set Expectations for TMO Q3 Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Stock analysts at Zacks Research dropped their Q3 2025 earnings per share estimates for Thermo Fisher Scientific in a research note issued on Tuesday, March 18th. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $5.79 per share for the quarter, down from their prior estimate of $5.80. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $23.28 per share.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%.

Several other brokerages have also weighed in on TMO. Citigroup lowered their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Scotiabank upped their price target on Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a "sector perform" rating in a research report on Monday, February 3rd. Morgan Stanley lifted their price objective on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an "overweight" rating in a report on Friday, January 31st. UBS Group raised their price target on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a "buy" rating in a research report on Friday, January 31st. Finally, Raymond James reaffirmed an "outperform" rating and set a $667.00 price objective (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Four equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and an average price target of $653.23.

Remove Ads

Thermo Fisher Scientific Stock Down 1.2 %

TMO stock traded down $6.13 during mid-day trading on Friday, hitting $513.77. 1,170,740 shares of the company were exchanged, compared to its average volume of 1,539,863. The company has a market capitalization of $193.83 billion, a PE ratio of 31.08, a price-to-earnings-growth ratio of 2.99 and a beta of 0.79. The firm has a fifty day simple moving average of $544.56 and a 200 day simple moving average of $554.22. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific has a twelve month low of $493.30 and a twelve month high of $627.88.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.33%. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.41%.

Insider Activity

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the sale, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. The trade was a 25.87 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the sale, the chief executive officer now directly owns 115,174 shares in the company, valued at $59,506,950.58. The trade was a 7.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 23,900 shares of company stock valued at $13,106,062. Insiders own 0.34% of the company's stock.

Hedge Funds Weigh In On Thermo Fisher Scientific

Several institutional investors have recently added to or reduced their stakes in TMO. Vanguard Group Inc. raised its stake in shares of Thermo Fisher Scientific by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 33,249,575 shares of the medical research company's stock worth $17,297,426,000 after buying an additional 196,864 shares during the last quarter. State Street Corp raised its position in shares of Thermo Fisher Scientific by 0.8% during the 3rd quarter. State Street Corp now owns 16,318,961 shares of the medical research company's stock valued at $10,100,655,000 after acquiring an additional 124,996 shares during the last quarter. Capital World Investors lifted its stake in shares of Thermo Fisher Scientific by 1.1% in the 4th quarter. Capital World Investors now owns 9,430,120 shares of the medical research company's stock valued at $4,905,812,000 after purchasing an additional 104,343 shares during the period. FMR LLC grew its stake in shares of Thermo Fisher Scientific by 19.7% during the third quarter. FMR LLC now owns 7,877,459 shares of the medical research company's stock worth $4,872,761,000 after purchasing an additional 1,294,453 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Thermo Fisher Scientific by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 7,857,385 shares of the medical research company's stock valued at $4,075,540,000 after purchasing an additional 197,442 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.